Beijing Hotgen Biotech Co., Ltd. (688068.SS)
CNY 52.76
(-1.59%)
CNY 52.76
(-1.59%)
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2023 | 17.21 Million CNY | -101.71% |
| 2022 | 1.09 Billion CNY | -57.79% |
| 2021 | 2.58 Billion CNY | 1919.85% |
| 2020 | 127.95 Million CNY | 242.37% |
| 2019 | 37.37 Million CNY | -33.03% |
| 2018 | 55.8 Million CNY | 61.3% |
| 2017 | 34.59 Million CNY | 15.02% |
| 2016 | 30.07 Million CNY | 0.0% |
| Year | Operating Income | Operating Income Growth |
|---|---|---|
| 2024 Q3 | -14.88 Million CNY | 68.66% |
| 2024 Q2 | -47.5 Million CNY | -972.49% |
| 2024 Q1 | 5.44 Million CNY | 108.45% |
| 2023 Q1 | 68.61 Million CNY | 133.36% |
| 2023 FY | -18.63 Million CNY | -101.71% |
| 2023 Q4 | -64.41 Million CNY | -61.82% |
| 2023 Q3 | -39.8 Million CNY | -334.65% |
| 2023 Q2 | 16.96 Million CNY | -75.28% |
| 2022 Q1 | 733.79 Million CNY | -13.28% |
| 2022 Q2 | 245.03 Million CNY | -66.61% |
| 2022 Q4 | -205.65 Million CNY | -187.36% |
| 2022 Q3 | 235.4 Million CNY | -3.93% |
| 2022 FY | 1.09 Billion CNY | -57.79% |
| 2021 Q3 | 10.84 Million CNY | -98.94% |
| 2021 Q2 | 1.01 Billion CNY | 44.09% |
| 2021 Q1 | 707.69 Million CNY | 462.19% |
| 2021 FY | 2.58 Billion CNY | 1919.85% |
| 2021 Q4 | 846.14 Million CNY | 7699.26% |
| 2020 Q4 | 125.88 Million CNY | 149566.82% |
| 2020 FY | 127.95 Million CNY | 242.37% |
| 2020 Q1 | 749.26 Thousand CNY | -96.69% |
| 2020 Q3 | -84.21 Thousand CNY | -105.99% |
| 2020 Q2 | 1.4 Million CNY | 87.63% |
| 2019 FY | 37.37 Million CNY | -33.03% |
| 2019 Q3 | 2.19 Million CNY | -85.05% |
| 2019 Q2 | 14.7 Million CNY | 772.86% |
| 2019 Q1 | -2.18 Million CNY | -106.17% |
| 2019 Q4 | 22.65 Million CNY | 930.33% |
| 2018 Q3 | 3.82 Million CNY | 0.0% |
| 2018 FY | 55.8 Million CNY | 61.3% |
| 2018 Q4 | 35.41 Million CNY | 826.63% |
| 2018 Q1 | 4.22 Million CNY | 0.0% |
| 2017 FY | 34.59 Million CNY | 15.02% |
| 2016 FY | 30.07 Million CNY | 0.0% |